New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-10-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-0900PMID 25324141PMCID PMC4268164
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

  2014cited by this paper
• Advances in understanding the leukaemia microenvironment

  2014cited by this paper
• Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

  2014cited by this paper
• CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

  2014cited by this paper
• Identification of pre-leukemic hematopoietic stem cells in acute leukemia

  2014cited by this paper
• NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2

  2013cited by this paper
• Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

  2013cited by this paper
• CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches

  2013cited by this paper
• The role of B7 family molecules in hematologic malignancy.

  2013cited by this paper
• Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

  2013influential reference
• BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

  2013cited by this paper
• Acute myelogenous leukemia stem cells: from Bench to Bedside.

  2013cited by this paper
• Immune evasion in acute myeloid leukemia: current concepts and future directions

  2013influential reference
• Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

  2013cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

  2013cited by this paper
• Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

  2013cited by this paper
• Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

  2013cited by this paper
• Minimal residual disease in acute myeloid leukaemia

  2013cited by this paper
• AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

  2013cited by this paper
• Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

  2013cited by this paper
• The origin and evolution of mutations in acute myeloid leukemia.

  2012cited by this paper
• A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• IDH mutation impairs histone demethylation and results in a block to cell differentiation

  2012cited by this paper
• A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

  2012cited by this paper
• Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.

  2012cited by this paper
• SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

  2012cited by this paper
• Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts

  2012cited by this paper
• Clonal architecture of secondary acute myeloid leukemia.

  2012cited by this paper
• Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

  2012influential reference
• Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

  2012cited by this paper
• RNAi screening of the kinome with cytarabine in leukemias.

  2012cited by this paper
• Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells

  2012cited by this paper
• Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

  2012cited by this paper
• DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

  2012cited by this paper
• Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

  2011cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

  2011cited by this paper
• Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

  2011cited by this paper
• Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

  2011cited by this paper
• MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

  2011cited by this paper
• Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

  2011cited by this paper
• Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

  2011cited by this paper
• Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.

  2011cited by this paper
• CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

  2011cited by this paper
• Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders

  2011cited by this paper
• Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

  2011cited by this paper
• Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

  2011cited by this paper
• Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.

  2010cited by this paper
• Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

  2010cited by this paper
• Targeting DNA repair pathways in AML.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

  2009cited by this paper
• Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

  2009cited by this paper
• PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

  2009cited by this paper
• Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

  2009cited by this paper
• The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology.

  2009cited by this paper
• Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

  2009cited by this paper
• CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy

  2009cited by this paper
• A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

  2009cited by this paper
• High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

  2008cited by this paper
• A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies

  2008cited by this paper
• Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

  2007cited by this paper
• Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase

  2007cited by this paper
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  2006influential reference
• CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.

  2006cited by this paper
• The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.

  2005cited by this paper
• Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

  2004cited by this paper
• CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

  2004cited by this paper
• Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

  2003cited by this paper
• Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

  2003cited by this paper
• Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer.

  2002influential reference
• Expression of Programmed Death 1 Ligands by Murine T Cells and APC1

  2002cited by this paper
• Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

  2001cited by this paper
• The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

  2000cited by this paper
• Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

  1997cited by this paper
• A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

  1994cited by this paper

• Notch activator cyclopiazonic acid induces apoptosis in HL-60 cells through calcineurin activation

  2023cites this paper
• microRNA-1246-containing extracellular vesicles from acute myeloid leukemia cells promote the survival of leukemia stem cells via the LRIG1-meditated STAT3 pathway

  2021cites this paper
• Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.

  2020cites this paper
• The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.

  2020cites this paper
• Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia

  2019cites this paper
• The prognostic value of matrix metalloproteinase‐7 and matrix metalloproteinase‐15 in acute myeloid leukemia

  2019cites this paper
• Signaling Landscape of AML: The Story So Far

  2018cites this paper
• Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

  2017cites this paper
• Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value

  2017cites this paper
• Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

  2017cites this paper
• The Effects of Frondoside A in Acute Leukemia

  2017cites this paper
• University of Dundee The blind men and the AML elephant

  2016cites this paper
• A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

  2016cites this paper
• Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia

  2016cites this paper
• The blind men and the AML elephant: can we feel the progress?

  2016cites this paper
• Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells.

  2016cites this paper
• Targeting novel signaling pathways for resistant acute myeloid leukemia.

  2015cites this paper
• Human bone marrow niche chemoprotection mediated by cytochrome p450 enzymes

  2015cites this paper
• Targeting cell cycle regulators in hematologic malignancies

  2015cites this paper